In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Calistoga Pharmaceuticals, Inc.

http://www.calistogapharma.com

Latest From Calistoga Pharmaceuticals, Inc.

Asia Deal Watch: Argo Partners RNAi Programs With Novartis In Major Biobucks Pact

Plus deals involving Biocytogen/Radiance, Maruho/AOBiome, LGChem/Rhythm, IASO/Umoja, JW Therapeutics/2seventy and 13 other transactions.

Deal Watch Business Strategies

Integra Buys Acclarent From J&J To Expand ENT 'Footprint'

Integra will pay $275m in cash plus $5m more in potential milestone incentive payments to add Acclarent’s ear, nose, and throat surgery devices to its existing neurosurgery portfolio.

M & A Ear, Nose & Throat

Orasis Prepares To Battle AbbVie In Presbyopia

The privately held firm got FDA approval for Qlosi, which like AbbVie’s Vuity is a low-dose formulation of pilocarpine for age-related near vision loss. Launch is planned for early 2024.

Approvals Business Strategies

Successful Cortrophin Gel Launch Could Drive Growth At ANI For Years To Come

The launch of ANI Pharmaceutical’s Cortrophin gel has reignited interest in the ACTH drug category, and appears set to drive growth at the company for the foreseeable future.

Sales & Earnings Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register